<DOC>
	<DOC>NCT01083719</DOC>
	<brief_summary>HYPOTHESIS AND SAMPLE SIZE The tumor delineated by FDG-PET is significantly different from the delineation achieved by MR T1 contrast weighted images in glioblastoma; expecting a standard error of 12.5 % (a confidence interval of 25%), with a confidence level set at 95%, a sample size of 15 patients would be accrued in the study.</brief_summary>
	<brief_title>A Comparison of FDG-PET Versus MRI Based Target Volume Delineation in Glioblastoma and the Role of FDG-PET/CT in the Alteration of MRI Based Target Volumes.</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<criteria>1. Post operative patients of documented high grade gliomas (grade III and IV) 2. Patients who have not undergone any previous irradiation to brain. 3. Performance Scale as defined by ECOG PS 03 1. Patients who are diabetic. 2. Patients who are pregnant. 3. Any documented contrast allergy to the agents used for imaging. 4. Patients who are unable to comprehend or cooperate effectively for treatment planning.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Glioblastoma</keyword>
	<keyword>FDG-PET</keyword>
	<keyword>MRI</keyword>
</DOC>